SYRA HEALTH CORP - CLASS A (SYRA) Fundamental Analysis & Valuation

NASDAQ:SYRAUS87168W2035

Current stock price

0.1043 USD
-0.02 (-17.94%)
At close:
0.0805 USD
-0.02 (-22.82%)
After Hours:

This SYRA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. SYRA Profitability Analysis

1.1 Basic Checks

  • SYRA had negative earnings in the past year.
  • In the past year SYRA has reported a negative cash flow from operations.
  • In the past 5 years SYRA always reported negative net income.
  • SYRA had a negative operating cash flow in each of the past 5 years.
SYRA Yearly Net Income VS EBIT VS OCF VS FCFSYRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

  • With a Return On Assets value of -102.17%, SYRA is not doing good in the industry: 94.29% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -130.59%, SYRA is doing worse than 80.95% of the companies in the same industry.
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROIC N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SYRA Yearly ROA, ROE, ROICSYRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • Looking at the Gross Margin, with a value of 20.71%, SYRA is in line with its industry, outperforming 41.90% of the companies in the same industry.
  • SYRA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for SYRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
SYRA Yearly Profit, Operating, Gross MarginsSYRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 20 -20 -40

4

2. SYRA Health Analysis

2.1 Basic Checks

  • SYRA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SYRA has been increased compared to 1 year ago.
  • Compared to 1 year ago, SYRA has a worse debt to assets ratio.
SYRA Yearly Shares OutstandingSYRA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly Total Debt VS Total AssetsSYRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1M 2M 3M 4M

2.2 Solvency

  • SYRA has an Altman-Z score of -2.79. This is a bad value and indicates that SYRA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -2.79, SYRA is doing worse than 85.71% of the companies in the same industry.
  • A Debt/Equity ratio of 0.05 indicates that SYRA is not too dependend on debt financing.
  • The Debt to Equity ratio of SYRA (0.05) is better than 78.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACC8.73%
SYRA Yearly LT Debt VS Equity VS FCFSYRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 2M -2M 4M

2.3 Liquidity

  • SYRA has a Current Ratio of 5.46. This indicates that SYRA is financially healthy and has no problem in meeting its short term obligations.
  • SYRA's Current ratio of 5.46 is amongst the best of the industry. SYRA outperforms 95.24% of its industry peers.
  • A Quick Ratio of 5.46 indicates that SYRA has no problem at all paying its short term obligations.
  • SYRA's Quick ratio of 5.46 is amongst the best of the industry. SYRA outperforms 95.24% of its industry peers.
Industry RankSector Rank
Current Ratio 5.46
Quick Ratio 5.46
SYRA Yearly Current Assets VS Current LiabilitesSYRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 1M 2M 3M 4M

3

3. SYRA Growth Analysis

3.1 Past

  • The earnings per share for SYRA have decreased by -8.98% in the last year.
  • The Revenue has grown by 44.67% in the past year. This is a very strong growth!
  • Measured over the past years, SYRA shows a very strong growth in Revenue. The Revenue has been growing by 78.22% on average per year.
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SYRA Yearly Revenue VS EstimatesSYRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2M 4M 6M 8M
SYRA Yearly EPS VS EstimatesSYRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 -0.1 -0.2 -0.3 -0.4 -0.5

0

4. SYRA Valuation Analysis

4.1 Price/Earnings Ratio

  • SYRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRA Price Earnings VS Forward Price EarningsSYRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRA Per share dataSYRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. SYRA Dividend Analysis

5.1 Amount

  • SYRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

SYRA Fundamentals: All Metrics, Ratios and Statistics

SYRA HEALTH CORP - CLASS A

NASDAQ:SYRA (4/17/2025, 8:00:00 PM)

After market: 0.0805 -0.02 (-22.82%)

0.1043

-0.02 (-17.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-11
Earnings (Next)05-07
Inst Owners6.21%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change0%
Market Cap1.18M
Revenue(TTM)7.98M
Net Income(TTM)-3.76M
AnalystsN/A
Price Target1.84 (1664.14%)
Short Float %0.68%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)4.36%
Min Revenue beat(2)-2.21%
Max Revenue beat(2)10.93%
Revenue beat(4)3
Avg Revenue beat(4)9.8%
Min Revenue beat(4)-2.21%
Max Revenue beat(4)22.54%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.15
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-0.54
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.26
FCFYN/A
OCF(TTM)-0.26
OCFYN/A
SpS0.71
BVpS0.25
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -102.17%
ROE -130.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.71%
FCFM N/A
ROA(3y)-84.41%
ROA(5y)N/A
ROE(3y)-167.47%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.1%
GM growth 5YN/A
F-Score4
Asset Turnover2.17
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 17.7%
Cap/Sales 0.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.46
Quick Ratio 5.46
Altman-Z -2.79
F-Score4
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)287.72%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%67.16%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)44.67%
Revenue growth 3Y78.22%
Revenue growth 5YN/A
Sales Q2Q%13.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-30.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.27%
OCF growth 3YN/A
OCF growth 5YN/A

SYRA HEALTH CORP - CLASS A / SYRA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of SYRA HEALTH CORP - CLASS A (SYRA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to SYRA.


Can you provide the valuation status for SYRA HEALTH CORP - CLASS A?

ChartMill assigns a valuation rating of 0 / 10 to SYRA HEALTH CORP - CLASS A (SYRA). This can be considered as Overvalued.


Can you provide the profitability details for SYRA HEALTH CORP - CLASS A?

SYRA HEALTH CORP - CLASS A (SYRA) has a profitability rating of 0 / 10.


What is the financial health of SYRA HEALTH CORP - CLASS A (SYRA) stock?

The financial health rating of SYRA HEALTH CORP - CLASS A (SYRA) is 4 / 10.